LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

MacroGenics Inc

Suletud

SektorTervishoid

1.71 -2.29

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.67

Max

1.78

Põhinäitajad

By Trading Economics

Sissetulek

4.8M

-36M

Müük

9M

22M

Kasumimarginaal

-162.992

Töötajad

341

EBITDA

5.7M

-33M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+155.68% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

19M

112M

Eelmine avamishind

4

Eelmine sulgemishind

1.71

Uudiste sentiment

By Acuity

75%

25%

346 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Neutral Evidence

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. sept 2025, 23:59 UTC

Omandamised, ülevõtmised, äriostud

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. sept 2025, 22:02 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Tron Shares Rise After New Investment From Bravemorning

8. sept 2025, 16:14 UTC

Suurimad hinnamuutused turgudel

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. sept 2025, 16:13 UTC

Suurimad hinnamuutused turgudel

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. sept 2025, 21:47 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4B AI Deal With Nebius

8. sept 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. sept 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. sept 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. sept 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. sept 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

8. sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. sept 2025, 16:59 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. sept 2025, 16:16 UTC

Tulu

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

155.68% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD  155.68%

Kõrge 5 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

1

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.47 / 1.64Toetus ja vastupanu

Lühikene perspektiiv

Neutral Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

346 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat